Compare Solaredge Technologies Inc (SEDG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs Sanofi SA — how do they compare? Solaredge Technologies Inc trades at $31.86 (market cap $2.00B), while Sanofi SA trades at $40.05 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 47.6× Solaredge Technologies Inc's market cap, and Sanofi SA pays a 6.01% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Solaredge Technologies Inc for 34 Days and Sanofi SA for 94 Days on average.
| SEDG | SNY | |
|---|---|---|
Market Cap | $2.00B | $95.18B |
Volume | 2,739,860 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $78.51 | $52.34 |
52-Week Low | $28.47 | $39.51 |
Typical Hold Time | 34 Days | 94 Days |
Enterprise Value | $1.86B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $33.16, down 2.59% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $405.45 million in 2025, with a negative net margin of -34.24%, though revenue improved to $1.18 billion. Recent news highlights an ongoing fraud investigation by Pomerantz Law Firm and ambitious long-term revenue targets of $2.4 billion by 2029, alongside new AI data center initiatives developed with NVIDIA.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests modest upside with a $37.75 price target. Key risks include execution on growth targets, competitive pressures, and macroeconomic headwinds affecting solar project financing. Institutional sentiment is cautious, with 56.25% hold ratings.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
